Dolutegravir Switch Maintains Second-Line HIV Suppression
Switching people living with HIV from a ritonavir-boosted protease inhibitor (PI) to a dolutegravir (Tivicay)-based regimen maintained viral suppression just as well, according to a randomized trial out of Kenya. Among a cohort of nearly 800 participants, 5.0% who switched to dolutegravir and 5.1% who continued taking a ritonavir-boosted PI had a plasma HIV type […]
First-Line HIV Treatment Proves Mettle in Pregnant Patients
The HIV agent dolutegravir (Tivicay) was tied to greater viral suppression for pregnant patients with HIV-1, according to a cohort study. Among patients who used dolutegravir during pregnancy, viral suppression at delivery was achieved in nearly 96.7% of participants, reported Kunjal Patel, DSc, of the Harvard T.H. Chan School of Public Health in Boston, and […]
Sex Disparity Mars Rollout of Embattled HIV Treatment in Poorer Countries
In low- and middle-income countries, dolutegravir (Tivicay) uptake in women still trailed that in men months after a safety reaffirmation from the World Health Organization (WHO), a large study showed. By March 2020, cumulative incidence of uptake of the antiretroviral by women ages 16-49 was 29.4% across 11 countries, compared with 57.7% in men of […]